MedMatrix Rx
Daily 340B Morning Briefing for Executives
The 340B Drug Pricing Program is facing significant changes and challenges as new policies and industry practices evolve. The Health Resources and Services Administration (HRSA) has approved a revised 340B rebate pilot for 2027, which will involve 21 drugs from ten manufacturers, effective January 1, 2027. In a related move, Johnson & Johnson has mandated that 340B covered entities submit claims-level data for outpatient drugs, with noncompliance resulting in pricing suspension. Meanwhile, the American Hospital Association (AHA) is advocating for a permanent ban on rebate models within the program, citing the administrative burdens these models impose. A recent report indicates that patients and payers spent $244.3 billion on 340B drugs in 2025. Concerns are rising about 340B hospitals lagging in charity care spending compared to their non-340B counterparts, raising questions about the program’s effectiveness in serving vulnerable populations.
EXECUTIVE SUMMARY
01
HRSA approves revised 340B rebate pilot for 2027.
HRSA has approved a revised 340B rebate pilot involving 21 drugs from ten manufacturers, effective January 1, 2027.
HRSA has approved a revised 340B rebate pilot involving 21 drugs from ten manufacturers, effective January 1, 2027.
Source: Healthcare Dive
02
J&J mandates claims data for 340B pricing.
Johnson & Johnson requires 340B covered entities to submit claims-level data for outpatient drugs or face pricing suspension.
Johnson & Johnson requires 340B covered entities to submit claims-level data for outpatient drugs or face pricing suspension.
Source: Becker’s Hospital Review
03
AHA seeks permanent ban on 340B rebate models.
The American Hospital Association urges Congress to permanently bar rebate models in the 340B program, citing administrative burdens.
The American Hospital Association urges Congress to permanently bar rebate models in the 340B program, citing administrative burdens.
Source: Becker’s Hospital Review
04
Patients and payers spend $244.3 billion on 340B drugs.
A report estimates patients and payers spent $244.3 billion on 340B drugs in 2025, more than double the 2021 total.
A report estimates patients and payers spent $244.3 billion on 340B drugs in 2025, more than double the 2021 total.
Source: Becker’s Hospital Review
05
340B hospitals lag in charity care spending.
340B hospitals spend a smaller share of their budgets on charity care compared to non-340B hospitals, according to a new report.
340B hospitals spend a smaller share of their budgets on charity care compared to non-340B hospitals, according to a new report.
Source: Healthcare Dive
06
ASHP advocates for 340B protections on Capitol Hill.
ASHP members are lobbying Congress for expanded Medicare coverage and protections for the 340B Drug Pricing Program.
ASHP members are lobbying Congress for expanded Medicare coverage and protections for the 340B Drug Pricing Program.
Source: Becker’s Hospital Review
07
Orphan drug policy impacts 340B pricing.
A pharmacist discusses the financial impact of orphan drug designations on 340B pricing for common conditions.
A pharmacist discusses the financial impact of orphan drug designations on 340B pricing for common conditions.
Source: STAT News
08
340B margin squeeze from new federal policies.
New federal policies and lower list prices are reducing 340B savings, impacting health centers more than hospitals.
New federal policies and lower list prices are reducing 340B savings, impacting health centers more than hospitals.
Source: Drug Channels
09
340B hospitals report less charity care than peers.
A report finds 340B hospitals spend less on charity care than non-340B hospitals, sparking debate on program benefits.
A report finds 340B hospitals spend less on charity care than non-340B hospitals, sparking debate on program benefits.
Source: Medical Daily
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The implications of these developments are significant for covered entities participating in the 340B program. The requirement for claims-level data from Johnson & Johnson could create administrative burdens, particularly for smaller entities that may lack the resources to comply. This, coupled with the potential for reduced savings due to new federal policies and the ongoing scrutiny regarding charity care spending, may strain the financial viability of many 340B hospitals and health centers. As the AHA pushes for a ban on rebate models, the 340B program could shift dramatically, impacting how covered entities manage their operations and serve their communities. The increased financial scrutiny and evolving regulatory environment necessitate that covered entities adapt swiftly to maintain their benefits under the program while ensuring they meet their obligations to provide charity care.
Emerging risks.
- Hospitals face potential cash flow disruptions due to the shift from upfront discounts to rebates.
- Noncompliance with J&J’s data submission requirements may lead to suspension of 340B pricing.
- Increased administrative burdens from new rebate models could strain hospital resources.
- 340B hospitals may face criticism for lower charity care spending compared to non-340B peers.
Emerging opportunities.
- Hospitals can use claims data to improve transparency and compliance with 340B requirements.
- Advocacy efforts could influence legislative changes favoring hospital interests in the 340B program.
- Participating in the HRSA rebate pilot may provide insights into optimizing drug procurement strategies.
- Engaging with policymakers on orphan drug pricing could lead to more favorable terms for hospitals.
Key actions for providers.
- Hospitals should prepare for the HRSA rebate pilot by updating financial and data reporting systems.
- Covered entities must ensure timely submission of claims data to maintain 340B pricing with J&J.
- Engage with AHA and ASHP to support advocacy efforts for favorable 340B legislative outcomes.
- Review and adjust charity care policies to address spending disparities in recent reports.
TOP STORIES
AHA seeks permanent ban on 340B rebate models.
Becker’s Hospital Review · September 25, 2026
- AHA urges Congress to permanently bar rebate models in the 340B program.
- The SECURE 340B Act includes new requirements and protections for hospitals.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
ASHP advocates for 340B protections on Capitol Hill.
Becker’s Hospital Review · September 16, 2026
- ASHP members lobby Congress for expanded Medicare coverage and 340B protections.
- Legislation includes the Main Street Pharmacy Access Act and Equitable Community Access to Pharmacist Services Act.
Orphan drug policy impacts 340B pricing.
STAT News · October 2, 2026
- A pharmacist discusses financial impacts of orphan drug designations on 340B pricing.
- HRSA’s 2013 rule on orphan drug exclusions was vacated by a federal court.
340B margin squeeze from new federal policies.
Drug Channels · September 29, 2026
- New federal policies and lower list prices are reducing 340B savings.
- Health centers are more affected than hospitals due to higher Part D drug share.
340B PROGRAM DEVELOPMENTS
Patients and payers spend $244.3 billion on 340B drugs.
Becker’s Hospital Review · October 1, 2026
- Patients and payers spent $244.3 billion on 340B drugs in 2025.
- This figure is more than double the $108.4 billion spent in 2021.
340B hospitals report less charity care than peers.
Medical Daily · September 28, 2026
- A report finds 340B hospitals spend less on charity care than non-340B hospitals.
- The report identifies a transparency gap in how 340B savings are used.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| E.D. Mo. | AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source] | September 24, 2026 |
| E.D. Mich. | Henry Ford Hospital v. CVS Health Corporation — Reply to Response to Motion. Case filed July 16, 2026. [source] | September 23, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Memorandum in support re Motion to Dismiss. Case filed July 2, 2026. [source] | September 23, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Objection to 5 motion for Preliminary Injunction Defendant’s Opposition to Plaintiff’s Motion for Preliminary Injunction. Case filed July 27, 2026. [source] | September 17, 2026 |
| 8th Cir. | Novartis Pharmaceuticals Corp. v. Catherine L. Hanaway — Judge order: The petition for rehearing en banc is denied. The petition for panel rehearing is also denied. Case filed March 28, 2025. [source] | September 16, 2026 |
| 8th Cir. | AbbVie, Inc. v. Marty Jackley — Motion to hold briefing schedule in abeyance. Case filed August 11, 2026. [source] | September 15, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| Johnson & Johnson | Requires claims data submission for 340B pricing; noncompliance leads to pricing suspension. [source] | September 11, 2026 |
WHAT TO WATCH NEXT
- Monitor HRSA’s implementation of the 340B rebate pilot starting January 1, 2027. [source]
- Watch for congressional response to AHA’s call for a permanent 340B rebate ban. [source]
- Follow developments in 340B litigation, including appeals and state law challenges. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.